Omphalos Signs MOU with FuriosaAI, KRIBB KPEC, Yonsei University, and Insilicox

Published by Omphalos Lifesciences on March 13, 2026March 13, 2026

We are excited to share that Omphalos Lifesciences Inc has joined a new industry–academia–research consortium to accelerate 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘂𝘀𝗶𝗻𝗴 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗺𝗽𝘂𝘁𝗶𝗻𝗴 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲.

On March 13, Omphalos Korea signed an MOU with FuriosaAI, Korea Research Institute of Bioscience and Biotechnology (KRIBB) Korea Preclinical Evaluation Center (KPEC), Yonsei University College of Pharmacy, and Insilicox to build a collaborative ecosystem for AI-powered drug development.

This partnership aims to integrate domestic NPU-based AI computing infrastructure with advanced digital biology platforms to accelerate innovation across the drug discovery pipeline.

Key areas of collaboration include:
• AI-driven drug discovery research
• Development of Digital AI Cells and digital biology platforms
• Bio-focused LLMs and data analytics platforms
• Next-generation bio-specialized computational logic
• Integration of data platforms with large-scale computing farms

Omphalos will contribute its programmable digital biology platform and digital cell modeling capabilities, helping expand the use of AI-powered simulation technologies in drug discovery.

By combining advanced AI semiconductor infrastructure with digital biology, this consortium aims to strengthen Korea’s emerging AI drug discovery ecosystem and accelerate the development of next-generation therapeutics.
We look forward to working with our partners to build the digital infrastructure that will power the future of biomedical innovation.

Press: 헤럴드경제, 디지털타임스, 뉴시스, 뉴스1, 쿠키뉴스, 충청뉴스, 지디넷